Annual report
177A.TEDINET S100TX40
Period2023-04-01 → 2024-03-31
Filed2024-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 120
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥4.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales |
| Revenue | ¥4.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥3.9bn | 2021-04-01 → 2022-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥597m | 2023-04-01 → 2024-03-31 | Cons. | Operating income |
| Operating income | ¥1.3bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Ordinary income | ¥636m | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥918m | 2021-04-01 → 2022-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥636m | 2023-04-01 → 2024-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥1.2bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥385m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥830m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥588m | 2021-04-01 → 2022-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥385m | 2023-04-01 → 2024-03-31 | Cons. | Profit loss |
| Net income | ¥830m | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Total assets | ¥6.6bn | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥6.1bn | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥5.6bn | at 2022-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥3.2bn | at 2024-03-31 | Cons. | Liabilities |
| Total liabilities | ¥3.1bn | at 2023-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥3.3bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥3.0bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥2.2bn | at 2022-03-31d | Cons. | Net assets |
| Cash and deposits | ¥1.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥1.5bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥1.7bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.5bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥1.7bn | at 2022-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥824m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥461m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥763m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥577m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥575m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | ¥83m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥1m | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥172m | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥360m | 2021-04-01 → 2022-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥92.43 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥199.23 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥173.5 | 2021-04-01 → 2022-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| Net assets per share | ¥802.5 | at 2024-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥724.57 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥532.27 | at 2022-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 50.7% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 49.2% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 39.6% | at 2022-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 12.1% | 2023-04-01 → 2024-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 31.7% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 31.2% | 2021-04-01 → 2022-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 159 | at 2024-03-31 | Cons. | Number of employees |
| Employees | 139 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 130 | at 2022-03-31d | Cons. | Number of employees |
| Revenue | ¥4.4bn | 2023-04-01 → 2024-03-31 | Standalone | Net sales |
| Revenue | ¥4.4bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥3.6bn | 2021-04-01 → 2022-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥3.3bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥2.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥445m | 2023-04-01 → 2024-03-31 | Standalone | Operating income |
| Operating income | ¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Ordinary income | ¥409m | 2023-04-01 → 2024-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥842m | 2021-04-01 → 2022-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥666m | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥456m | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥423m | 2023-04-01 → 2024-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥1.1bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Net income | ¥212m | 2023-04-01 → 2024-03-31 | Standalone | Profit loss |
| Net income | ¥751m | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥564m | 2021-04-01 → 2022-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥685m | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥303m | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥6.0bn | at 2024-03-31 | Standalone | Assets |
| Total assets | ¥5.8bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥5.3bn | at 2022-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.8bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥4.2bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥3.2bn | at 2024-03-31 | Standalone | Liabilities |
| Total liabilities | ¥3.0bn | at 2023-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥2.8bn | at 2024-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.7bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥2.0bn | at 2022-03-31d | Standalone | Net assets |
| Net assets / equity | ¥1.4bn | at 2021-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥748m | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥1.2bn | at 2024-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥1.0bn | at 2023-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥50.9 | 2023-04-01 → 2024-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥180.37 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥166.59 | 2021-04-01 → 2022-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥2,023.85 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥896.59 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| Dividend per share | ¥14 | 2023-04-01 → 2024-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥19 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2021-04-01 → 2022-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥45 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥683.18 | at 2024-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥651.21 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥480.9 | at 2022-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥4,121.96 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,105.69 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 47.2% | at 2024-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 47.2% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 38.0% | at 2022-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 28.9% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.3% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 7.6% | 2023-04-01 → 2024-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 31.9% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 33.2% | 2021-04-01 → 2022-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 64.7% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 54.7% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 4,165,000 | at 2024-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 4,165,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 416,500 | at 2022-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 338,500 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 338,500 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 135 | at 2024-03-31 | Standalone | Number of employees |
| Employees | 117 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 108 | at 2022-03-31d | Standalone | Number of employees |
| Employees | 98 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 101 | at 2020-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 42
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | depreciation | 2023-04-01 → 2024-03-31 | ¥15m |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2024-03-31 | −¥415m |
| Cell Process Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥114m |
| Cell Process Businessreportable segment | employees | at 2024-03-31 | 36 pure |
| Cell Process Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Cell Process Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.2bn |
| Cell Process Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥472m |
| Microbiological Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥100m |
| Microbiological Businessreportable segment | employees | at 2024-03-31 | 50 pure |
| Microbiological Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Microbiological Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.7bn |
| Microbiological Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | −¥69m |
| Tissue Culture Businessreportable segment | depreciation | 2023-04-01 → 2024-03-31 | ¥69m |
| Tissue Culture Businessreportable segment | employees | at 2024-03-31 | 59 pure |
| Tissue Culture Businessreportable segment | revenue | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Tissue Culture Businessreportable segment | revenue external | 2023-04-01 → 2024-03-31 | ¥1.9bn |
| Tissue Culture Businessreportable segment | segment profit | 2023-04-01 → 2024-03-31 | ¥609m |
| —segment total | depreciation | 2023-04-01 → 2024-03-31 | ¥284m |
| —segment total | revenue | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| —segment total | revenue external | 2023-04-01 → 2024-03-31 | ¥4.8bn |
| —segment total | segment profit | 2023-04-01 → 2024-03-31 | ¥1.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥13m |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥353m |
| Cell Process Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥20m |
| Cell Process Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥697m |
| Cell Process Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥697m |
| Cell Process Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥281m |
| Microbiological Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥85m |
| Microbiological Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥2.4bn |
| Microbiological Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥2.4bn |
| Microbiological Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥818m |
| Tissue Culture Businessreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥46m |
| Tissue Culture Businessreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Tissue Culture Businessreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Tissue Culture Businessreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥522m |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥151m |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥4.7bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥4.7bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥1.6bn |
| Cell Process Businessreportable segment | employees | at 2024-03-31 | 36 pure |
| Microbiological Businessreportable segment | employees | at 2024-03-31 | 45 pure |
| Tissue Culture Businessreportable segment | employees | at 2024-03-31 | 40 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,335
| Item | Context | Value | Unit |
|---|---|---|---|
| Provision of allowance for doubtful accounts sga | Prior1YearDuration_NonConsolidatedMember | 1772000 | JPY |
| Provision of allowance for doubtful accounts sga | CurrentYearDuration_NonConsolidatedMember | 20023000 | JPY |
| Salaries and allowances oecna | Prior1YearDuration_NonConsolidatedMember | 272645000 | JPY |
| Salaries and allowances oecna | CurrentYearDuration_NonConsolidatedMember | 251717000 | JPY |
| Commission fee sga | Prior1YearDuration_NonConsolidatedMember | 225459000 | JPY |
| Commission fee sga | CurrentYearDuration_NonConsolidatedMember | 267079000 | JPY |
| Provision for bonuses sga | Prior1YearDuration_NonConsolidatedMember | 26464000 | JPY |
| Provision for bonuses sga | CurrentYearDuration_NonConsolidatedMember | 23991000 | JPY |
| Retirement benefit expenses sga | Prior1YearDuration_NonConsolidatedMember | 8393000 | JPY |
| Retirement benefit expenses sga | CurrentYearDuration_NonConsolidatedMember | 2079000 | JPY |
| Depreciation sga | Prior1YearDuration_NonConsolidatedMember | 36630000 | JPY |
| Depreciation sga | CurrentYearDuration_NonConsolidatedMember | 38944000 | JPY |
| Research and development expenses sga | Prior1YearDuration_NonConsolidatedMember | 161282000 | JPY |
| Research and development expenses sga | CurrentYearDuration_NonConsolidatedMember | 240003000 | JPY |
| Document title cover page | FilingDateInstant | Original text (Japanese)有価証券報告書 | |
| Clause of stipulation cover page | FilingDateInstant | Original text (Japanese)金融商品取引法第24条第１項 | |
| Place of filing cover page | FilingDateInstant | Original text (Japanese)関東財務局長 | |
| Filing date cover page | FilingDateInstant | 2024-06-28 | |
| Fiscal year cover page | FilingDateInstant | Original text (Japanese)第43期(自 2023年４月１日 至 2024年３月31日) | |
| Company name cover page | FilingDateInstant | Original text (Japanese)コージンバイオ株式会社 | |
| Company name in english cover page | FilingDateInstant | Kohjin Bio Co., Ltd. | |
| Title and name of representative cover page | FilingDateInstant | Original text (Japanese)代表取締役社長 中村 孝人 | |
| Address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)埼玉県坂戸市千代田五丁目１番地３ | |
| Telephone number address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)049－284－3781(代表) | |
| Name of contact person address of registered headquarter cover page | FilingDateInstant | Original text (Japanese)上席執行役員管理統括 平田 賢二 | |
| Nearest place of contact cover page | FilingDateInstant | Original text (Japanese)東京都豊島区西池袋一丁目11番１号 | |
| Telephone number nearest place of contact cover page | FilingDateInstant | 03－5784－2272 | |
| Name of contact person nearest place of contact cover page | FilingDateInstant | Original text (Japanese)上席執行役員管理統括 平田 賢二 | |
| Place for public inspection cover page (text) | FilingDateInstant | Text · Plus | |
| Edinet code | FilingDateInstant | E38689 | |
| Fund code | FilingDateInstant | － | |
| Security code | FilingDateInstant | 177A0 | |
| Filer name in japanese | FilingDateInstant | Original text (Japanese)コージンバイオ株式会社 | |
| Filer name in english | FilingDateInstant | Kohjin Bio Co., Ltd. | |
| Fund name in japanese | FilingDateInstant | － | |
| Fund name in english | FilingDateInstant | － | |
| Cabinet office ordinance | FilingDateInstant | Original text (Japanese)企業内容等の開示に関する内閣府令 | |
| Document type | FilingDateInstant | Original text (Japanese)第三号様式 | |
| Accounting standards | FilingDateInstant | Japan GAAP | |
| Whether consolidated financial statements are prepared | FilingDateInstant | true | |
| Industry code when consolidated financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Industry code when financial statements are prepared in accordance with industry specific regulations | FilingDateInstant | cte | |
| Current fiscal year start date | FilingDateInstant | 2023-04-01 | |
| Current period end date | FilingDateInstant | 2024-03-31 | |
| Type of current period | FilingDateInstant | FY | |
| Current fiscal year end date | FilingDateInstant | 2024-03-31 | |
| Previous fiscal year start date | FilingDateInstant | 2022-04-01 | |
| Comparative period end date | FilingDateInstant | 2023-03-31 | |
| Previous fiscal year end date | FilingDateInstant | 2023-03-31 | |
| Next fiscal year start date | FilingDateInstant | － |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |